PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a systematic review and meta-analysis

Francesco Schettini, Tomas Pascual, Benedetta Conte, Nuria Chic, Fara Brasò-Maristany, Patricia Galvàn, Olga Martìnez, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Aranzazu Fernandez-Martinez, Carla Rognoni, Gaia Griguolo, Valentina Guarneri, Pierfranco Conte, Mariavittoria Loccia, Jan Brase, Blanca Gonzalez-Farre, Patricia Villagrasa, Sabino De Placido, Rachel Schiff, Mothaffar Rimawi, C Osborne, Sonia Pernas, Charles Perou … & Aleix Prat
HER2-positive (HER2+) breast cancer (BC) comprises all the PAM50 intrinsic molecular subtypes (Luminal A, Luminal B, HER2-E and Basal-like). Among them, the HER2-E is associated with higher pathological complete response (pCR) rates compared to non-HER2-E disease following anti-HER2-based regimens, with or without chemotherapy (CT). Here, we present a trial-level metanalysis to validate the association of the HER2-E subtype with pCR.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.